Reckitt Benckiser Group, a provider of hygiene, wellness and nourishment products, agreed to acquire Biofreeze and TheraPearl, two providers of over-the-counter topical pain relief with gel, roll-on, spray, cream and patch formats, from Madison Dearborn Partners, a private equity firm. The transaction is subject to certain regulatory approvals as well as other customary closing conditions and completion is currently expected in Q2 2021. Financial terms were not disclosed. "We see compelling opportunities to develop the topical pain relief category globally with Biofreeze and other RB pain management brands including Nurofen, Moov and Tempra. The brand taps into the growing global trend for wellness and self-care and aligns with our strategy to build our US Health footprint into new spaces and places," Laxman Narasimhan, RB Chief Executive Officer.